Breath Test Expansion
Cannabix Technologies Expands Breath Test Capabilities to Detect Methamphetamine and Amphetamine
Cannabix Technologies has detected methamphetamine and amphetamine in human breath samples — a first for the company's Marijuana Breath Test (MBT) device. The announcement, made on July 2, 2026, signals that the Canadian breath-testing firm is expanding well beyond cannabis into the broader drug testing market, according to Financial Post.
CEO Rav Mlait called the findings a "significant new opportunity" that validates the MBT's ability to detect stimulants, not just THC. The company believes the discovery could help it compete in a global drug testing market valued at $15.9 billion, per Fort McMurray Today.
How Breath Testing Catches Drugs That Aren't Alcohol
Unlike alcohol, drugs like methamphetamine and THC don't evaporate into breath on their own. They travel in microscopic aerosol particles exhaled from deep in the lungs. Cannabix's Breath Collection Unit (BCU) captures those particles. Its lab partner, Omega Laboratories, then uses liquid chromatography-mass spectrometry (LC-MS) — a highly precise lab method — to identify trace drug compounds, according to Sault Star.
The detection threshold for THC is just 5 picograms per liter of breath — an extremely small amount. That sensitivity is what makes the system forensically credible. A March 2026 study in the Journal of Analytical Toxicology validated the Cannabix/Omega method, confirming breath aerosol results can match recent blood drug levels, per Brantford Expositor.
A 4-Hour Window Makes This Legally Defensible for Employers
The MBT only detects drug use within roughly 4 hours. That's far shorter than urine tests, which flag use up to 30 days back, or hair tests, which can go months. That short window matters enormously. In April 2026, the U.S. Department of Justice rescheduled marijuana to Schedule III, meaning employers can no longer fire workers simply for testing positive on a urine test without risking legal trouble, according to Woodstock Sentinel Review.
A breath test that only catches recent use gives employers a legally safer path. It shows a worker was likely impaired at the time of the test — not just that they smoked cannabis last weekend. Cannabix made its first major industrial deployment in June 2026 with a heavy materials company in Québec, per Chatham Daily News.
Adding Meth Detection Pushes Cannabix Into a Much Bigger Market
Before this announcement, Cannabix was seen as a "marijuana-only" company. Detecting methamphetamine and amphetamine changes that. The global drug testing services market is on track to hit $4.5 billion by late 2026, growing at a 6.3% annual rate, with North America holding nearly 40% of the market, according to Hanna Herald.
The addition of stimulants lets the MBT compete with multi-panel urine tests — the current industry standard — while still offering a shorter, more impairment-relevant detection window. High-risk industries like mining, oil and gas, and long-haul trucking are seen as the prime targets for adoption, per The Observer.
Civil Liberties Groups Warn Against Broader Breathalyzer Surveillance
Not everyone sees the expansion as a win. Civil liberties advocates and labor analysts warn that a device that can now screen for multiple drugs — quickly and without a needle — could normalize mass testing in workplaces that don't involve safety risks. The concern is "pervasive surveillance" creeping into ordinary jobs, according to Pinchin Creek Echo.
Legal experts also caution that detecting a drug in breath still doesn't prove impairment the way a blood alcohol content (BAC) reading does for alcohol. A positive breath test shows recent use — not that a person's judgment or reflexes are actually compromised. That distinction could matter greatly in future court challenges, per Stratford Beacon Herald.
Sentiment
NeutralPublishers
17
Articles
17
Reach
17
